

**Yotam Levin, MD, MBA**

**CEO**

**NanoPass Technologies Ltd.**

Yotam is the CEO of NanoPass, a clinical innovation company working to improve vaccines and immunotherapies using a novel injection device, the first of its kind to ever register with FDA, EMEA, and China FDA. Yotam has led the team, and product development, from concept to commercial operations and has commercialized the device in the EU, US, China and Brazil. As an MD he also leads the Company's clinical development strategy, and conceived, initiated or supported nearly 60 clinical trials all over the world with Big Pharma, Biotech, NIH, CDC and others. During the COVID pandemic Yotam became a Medical Advisor to the Israeli Institute for Biological Research (Machon Biology) and led protocol design and development for the rVSV COVID vaccine. A member of the 8400 Health Network (Cohort 2), Yotam was involved in establishing its mentoring program, as well as in co-leading the vaccine working group that was established to support vaccine development and policy in Israel. Yotam received his MD and MBA from Tel Aviv University, and in his spare time does solo hikes, volunteers at "Variety" and teaches healthcare entrepreneurship.